Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome
- PMID: 20883238
- PMCID: PMC8673323
- DOI: 10.1111/j.1751-7176.2010.00339.x
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome
Comment in
-
Spironolactone revisited.J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18. J Clin Hypertens (Greenwich). 2011. PMID: 21974769 Free PMC article. No abstract available.
References
-
- Garrison RJ, Kannel WB, Stokes J 3rd, et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16:235–251. - PubMed
-
- Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625–633. - PubMed
-
- He J, Whelton PK, Appel JL, et al. Long‐term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544–549. - PubMed
-
- Strazzullo P, Galletti F, Barba G. Altered renal handling of sodium in human hypertension. Hypertension. 2003;41:1000–1005. - PubMed
-
- Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity‐induced hypertension. Hypertension. 1994;23(1 supp):I8–I11. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
